Nicolas Wisniacki

618 total citations
12 papers, 396 citations indexed

About

Nicolas Wisniacki is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Nicolas Wisniacki has authored 12 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 5 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Nicolas Wisniacki's work include Systemic Sclerosis and Related Diseases (5 papers), NF-κB Signaling Pathways (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Nicolas Wisniacki is often cited by papers focused on Systemic Sclerosis and Related Diseases (5 papers), NF-κB Signaling Pathways (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Nicolas Wisniacki collaborates with scholars based in United Kingdom, United States and Netherlands. Nicolas Wisniacki's co-authors include Linda C. Burkly, Chaim Putterman, Jennifer S. Michaelson, Gerald R. Galluppi, Ray Zhang, Timothy S. Zheng, Jessica Kong, Lakshmi Amaravadi, André van Maurik and Chiara Zecchin and has published in prestigious journals such as Diabetologia, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Nicolas Wisniacki

12 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Wisniacki United Kingdom	10	165	113	97	70	68	12	396
Zuzana Mikulková Czechia	10	198 1.2×	92 0.8×	115 1.2×	72 1.0×	101 1.5×	22	450
Š Rùzicková Czechia	11	203 1.2×	110 1.0×	168 1.7×	61 0.9×	48 0.7×	20	463
Lorraine Yeo United Kingdom	11	210 1.3×	172 1.5×	153 1.6×	101 1.4×	27 0.4×	17	508
Maki Fujishiro Japan	13	114 0.7×	148 1.3×	205 2.1×	112 1.6×	59 0.9×	30	453
Maciej Cabanski Switzerland	7	76 0.5×	65 0.6×	103 1.1×	34 0.5×	75 1.1×	9	316
Junyan Qian China	12	125 0.8×	90 0.8×	126 1.3×	123 1.8×	35 0.5×	40	418
Wenhan Du China	10	194 1.2×	100 0.9×	91 0.9×	52 0.7×	18 0.3×	12	342
Justyna Chwiećko Poland	13	125 0.8×	287 2.5×	98 1.0×	93 1.3×	69 1.0×	27	533
Angela B Mobley United States	6	376 2.3×	178 1.6×	162 1.7×	73 1.0×	41 0.6×	8	656
Martin Judex Germany	11	137 0.8×	233 2.1×	147 1.5×	110 1.6×	44 0.6×	19	477

Countries citing papers authored by Nicolas Wisniacki

Since Specialization

Citations

This map shows the geographic impact of Nicolas Wisniacki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Wisniacki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Wisniacki more than expected).

Fields of papers citing papers by Nicolas Wisniacki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Wisniacki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Wisniacki. The network helps show where Nicolas Wisniacki may publish in the future.

Co-authorship network of co-authors of Nicolas Wisniacki

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Wisniacki. A scholar is included among the top collaborators of Nicolas Wisniacki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Wisniacki. Nicolas Wisniacki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Mariette, Xavier, Francesca Barone, Chiara Baldini, et al.. (2022). A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 7(23). 70 indexed citations

Denton, Christopher P., Francesco Del Galdo, Dinesh Khanna, et al.. (2022). Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Lara D. Veeken. 62(1). 234–242. 20 indexed citations

Mariette, Xavier, Chiara Baldini, Francesca Barone, et al.. (2021). OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY. Annals of the Rheumatic Diseases. 80. 78–79. 9 indexed citations

Clark, Kristina E N, Corrado Campochiaro, Eszter Csomor, et al.. (2021). Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases. 80(12). 1584–1593. 23 indexed citations

Keymeulen, Bart, André van Maurik, David R. Inman, et al.. (2020). A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia. 64(2). 313–324. 38 indexed citations

Wan, Qi, Jonathan A. Wilks, Mary Feeney, et al.. (2020). The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis. Arthritis Research & Therapy. 22(1). 179–179. 26 indexed citations

Groot, Marius de, Neel Patel, Roido Manavaki, et al.. (2019). Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI. EJNMMI Research. 9(1). 113–113. 10 indexed citations

Reid, Juliet, Stefano Zamuner, Maria Feeney, et al.. (2018). In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody. British Journal of Clinical Pharmacology. 84(10). 2280–2291. 33 indexed citations

Stawski, Lukasz, et al.. (2017). THU0026 Osm is more effective than il-6 at inducing endomt of human dermal microvascular cells. Annals of the Rheumatic Diseases. 76. 209–209. 2 indexed citations

10.

Galluppi, Gerald R., et al.. (2016). Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti‐TNF‐like weak inducer of apoptosis (anti‐TWEAK) monoclonal antibody. British Journal of Clinical Pharmacology. 82(1). 118–128. 15 indexed citations

11.

Wisniacki, Nicolas, Lakshmi Amaravadi, Gerald R. Galluppi, et al.. (2013). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis. Clinical Therapeutics. 35(8). 1137–1149. 53 indexed citations

12.

Michaelson, Jennifer S., Nicolas Wisniacki, Linda C. Burkly, & Chaim Putterman. (2012). Role of TWEAK in lupus nephritis: A bench-to-bedside review. Journal of Autoimmunity. 39(3). 130–142. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact